Close Menu

mergers & acquisitions

Hologic intends to invest in assay development for Mobidiag's Novodiag PCR platform, which provides high-level multiplexing to detect infectious disease organisms.

Invitae expects that Genosity's software and data management platform will allow it to quickly advance several oncology tests in development.

The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.

Illumina said it plans to "vigorously defend" the deal and oppose the FTC, which previously helped scuttle Illumina's proposed acquisition of Pacific Biosciences.

The firm said that due to a negative coverage decision and capital constraints, it is evaluating options including a sale by a public takeover or an asset deal.

PWNHealth will be rebranded as Everly Health Solutions and will operate as an independent subsidiary of newly-formed parent company Everly Health.

NeoGenomics will offer Trapelo's clinical decision support system to providers, payors, and labs to aid precision oncology across all healthcare settings.

Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.

The company uses next-generation sequencing data to track the health of transplanted organs and stem cells over time.

Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.

Pages